Merrimack Pharma (MACK) Tops Q2 EPS by 10c

Merrimack Pharma (NASDAQ: MACK) reported Q2 EPS of ($0.21), $0.10 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $36.6 million versus the consensus estimate of $17.57 million.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS says bull market has further to run
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance